bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figures 1-5 from PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
Authors: Dudgeon Crissy , Wang Peng , Sun Xiameng , Peng Rui , Sun Quanhong , Yu Jian , Zhang Lin
Published: April 2023

Supplementary Figures 1-5 from PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01
Supplementary Figure 8 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 89K, HPLC and Mass spectrometric analysis of mice plasma and tumor tissues for the bioavailability of SENL compounds after oral administration of SENL, 200 mg/kg body weight. A, HPLC chromatogram of plasma of mice treated with SENL. B, HPLC chromatogram of LNCaP xenograft tumor tissue of mice treated with SENL. C, The mass spectrometric analysis of mice tumor tissue fraction 1 obtained from HPLC depicts the M ion at 488.1824 m/z, suggestive by mass alone as the sodium salt of nimbolide. D, The mass spectrometric analysis of mice tumor tissue fraction 2 obtained from HPLC depicts the M ion at 452.2195 m/z, suggestive by mass alone as the 28-deoxonimbolide. HPLC and mass spectrometric analysis was performed in duplicate, representative chromatograms were shown. The difference between the measured value for the sodium salt of nimbolide standard from the measured value in plasma and tumor tissue is less than 2.8 ppm and for 28-deoxonimbolide in the tumor tissues from the calculated value is less than 1 ppm.
Supplementary Figure 7 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 103K, Molecular structures for the compounds shown in the mass spectrum are depicted.
Supplementary Table 1 from In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Authors: Hollevoet Kevin , Mason-Osann Emily , Liu Xiu-fen , Imhof-Jung Sabine , Niederfellner Gerhard , Pastan Ira
Published: April 2023

PDF - 60K, Toxicity studies for RG7787 were performed in athymic nude mice. General health and weight was evaluated during therapy.
Supplementary Figure 6 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 46K, Mass spectrometric analysis of SENL fraction 14 obtained from HPLC and the standards nimbolide and 2′, 3′-dehydrosalannol. The total ion chromatogram retention time and the mass spectrum of individual peaks are depicted in the panel A to C, respectively.
Supplementary Materials and Methods and Supplementary Figure Legends from In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
Authors: Hollevoet Kevin , Mason-Osann Emily , Liu Xiu-fen , Imhof-Jung Sabine , Niederfellner Gerhard , Pastan Ira
Published: April 2023

PDF - 261K, Supplementary methods related to the IHC protocol and supplementary figure legends.
Supplementary Figure 3 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 79K, Mass spectrometric analysis of SENL fractions 2, 3, and 4 obtained from HPLC. The total ion chromatogram retention time and the mass spectrum of individual peaks for the fractions 2, 3, and 4 are depicted in the panel A to C, respectively.
Supplementary Figure 2 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 185K, The peaks labeled in the HPLC chromatogram were evaluated for cytotoxic activity against PC3 cells. The fractions collected from HPLC were concentrated using SpeedVac at 4 degrees C, and equal weights of the fractions were reconstituted in ethanol. PC3 cells were treated with serial dilutions of the fractions for 24 hours, and the viability was determined using the MTS assay.
Supplementary Table 1 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

XLSX file - 79KB, Genes regulated by pentamidine in 786-O cells after 6h incubation.
Supplementary Figure 1 from Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Authors: Wu Qiang , Kohli Manish , Bergen H. Robert. , Cheville John C. , Karnes R. Jeffrey , Cao Hong , Young Charles Y.F. , Tindall Donald J. , McNiven Mark A. , Donkena Krishna Vanaja
Published: April 2023

PDF - 113K, Fractionation of SENL was performed using a Kinetex C18 column on a Shimadzu HPLC system. The experiments were performed in triplicate; a representative HPLC chromatogram of SENL is shown.
Supplementary Methods from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 93KB
Supplementary Figure Legends from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 76KB
Supplementary Figure 8 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 953KB, Heatmap of top up- and down-regulated genes in response to pentamidine 25 microM treatment of 786-O cells for 6 hrs.
Supplementary Figure S4 from Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Authors: Mondini Michele , Nizard Mevyn , Tran Thi , Mauge Laetitia , Loi Mauro , Clémenson Céline , Dugue Delphine , Maroun Pierre , Louvet Emilie , Adam Julien , Badoual Cécile , Helley Dominique , Dransart Estelle , Johannes Ludger , Vozenin Marie-Catherine , Perfettini Jean-Luc , Tartour Eric , Deutsch Eric
Published: April 2023

Tumor vessels staining is not significantly affected by treatments
Supplementary Figure 7 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 446KB, Apoptosis assay for RCC4 VHL (-) RCC4 VHL (+) cell lines.
Supplementary Figure S3 from Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Authors: Mondini Michele , Nizard Mevyn , Tran Thi , Mauge Laetitia , Loi Mauro , Clémenson Céline , Dugue Delphine , Maroun Pierre , Louvet Emilie , Adam Julien , Badoual Cécile , Helley Dominique , Dransart Estelle , Johannes Ludger , Vozenin Marie-Catherine , Perfettini Jean-Luc , Tartour Eric , Deutsch Eric
Published: April 2023

Combination treatment induces a long-term anti-metastatic immune response
Supplementary Figure 6 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 1103KB, Apoptosis assay for (A) VHL (-) and (B) VHL (+) 786-O RCC cells treated with pentamidine 100, 50, 20 and 10 microM, olygomycin 1, 0.5, 0.2 and 0.1 microM, oxaprozin 300, 150, 60 and 30 microM and dopamine 1, 0.5, 0.2 and 0.1 microM for 24 hours.
Supplementary Figure S2 from Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Authors: Mondini Michele , Nizard Mevyn , Tran Thi , Mauge Laetitia , Loi Mauro , Clémenson Céline , Dugue Delphine , Maroun Pierre , Louvet Emilie , Adam Julien , Badoual Cécile , Helley Dominique , Dransart Estelle , Johannes Ludger , Vozenin Marie-Catherine , Perfettini Jean-Luc , Tartour Eric , Deutsch Eric
Published: April 2023

CTLA4, PD1 and Tim3 expression on CD8+ T cells is not modulated by combination treatment
Supplementary Figure S1 from Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer
Authors: Mondini Michele , Nizard Mevyn , Tran Thi , Mauge Laetitia , Loi Mauro , Clémenson Céline , Dugue Delphine , Maroun Pierre , Louvet Emilie , Adam Julien , Badoual Cécile , Helley Dominique , Dransart Estelle , Johannes Ludger , Vozenin Marie-Catherine , Perfettini Jean-Luc , Tartour Eric , Deutsch Eric
Published: April 2023

KRN7000 adjuvant or low doses irradiation does not modify tumor response
Supplementary Figure 4 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 1679KB, Apoptosis assay for (A) UOK and (B) ACHN RCC cells treated with amitriptyline 0.025 and 0.05 microM, pentamidine 20 microM, olygomycin 0.2 microM, oxaprozin 150 microM, dopamine 0.2 microM and combinations of each 2 or 3 drugs in the same concentrations for 24 hours.
Supplementary Table 2 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 19K, Sense and antisense primer sequences of various genes used in RT-PCR assays.
Supplementary Figure 2 from Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer
Authors: Zerbini Luiz Fernando , Bhasin Manoj K. , de Vasconcellos Jaira F. , Paccez Juliano D. , Gu Xuesong , Kung Andrew L. , Libermann Towia A.
Published: April 2023

PDF file - 426KB, Hierarchical clustering of ccRCC patients based on IBA-derived gene signatures.
Supplementary Table 1 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 19K, Sense and antisense primer sequences of various genes used in q-RT-PCR assays.
Supplementary Figure 6 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 39K, Effect of mahanine on growth of non-tumorigenic and tumorigenic prostate epithelial cells.
Supplementary Methods from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 59K
Supplementary Figure 3 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 189K, Effect of mahanine on various androgen-regulated genes quantified by semi-quantitative PCR.
Supplementary Figure 2 from FAK Inhibition Disrupts a β5 Integrin Signaling Axis Controlling Anchorage-Independent Ovarian Carcinoma Growth
Authors: Tancioni Isabelle , Uryu Sean , Sulzmaier Florian J. , Shah Nina R. , Lawson Christine , Miller Nichol L.G. , Jean Christine , Chen Xiao Lei , Ward Kristy K. , Schlaepfer David D.
Published: April 2023

PDF file - 315K, Cell survival and cell cycle progression analyses of VS-4718 FAK inhibitor sensitive (HEY and OVCAR8) and resistant (OVCAR10 and SKOV3-IP) cells.
Supplementary Figure 1 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 42K< Chemical structure of mahanine.
Supplementary Figure Legend from Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Authors: Gadhikar Mayur A. , Sciuto Maria Rita , Alves Marcus Vinicius Ortega , Pickering Curtis R. , Osman Abdullah A. , Neskey David M. , Zhao Mei , Fitzgerald Alison L. , Myers Jeffrey N. , Frederick Mitchell J.
Published: April 2023

PDF file - 55 KB
Supplementary Figure 1 from Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Authors: Gadhikar Mayur A. , Sciuto Maria Rita , Alves Marcus Vinicius Ortega , Pickering Curtis R. , Osman Abdullah A. , Neskey David M. , Zhao Mei , Fitzgerald Alison L. , Myers Jeffrey N. , Frederick Mitchell J.
Published: April 2023

PDF file - 5 MB, Apoptosis is not the main mode of cell death in wtp53 HNSCC cells.
Supplementary Materials and Methods from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 80K, Supplementary Materials and Methods
Supplementary Figure Legend from Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB
Authors: Schech Amanda J. , Kazi Armina A. , Gilani Rabia A. , Brodie Angela H.
Published: April 2023

PDF file - 31K
Supplementary Figure 5 from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 174K, Examples of DNA histograms from LCC9 and MCF-7 cells treated with combinations of ERbeta-selective ligands and chloroquine.
Supplementary Figure 3 from Zoledronic Acid Reverses the Epithelial–Mesenchymal Transition and Inhibits Self-Renewal of Breast Cancer Cells through Inactivation of NF-κB
Authors: Schech Amanda J. , Kazi Armina A. , Gilani Rabia A. , Brodie Angela H.
Published: April 2023

PDF file - 52K, Zoledronic acid inactivates NFκB, and inhibits interactions between RelA and the Twist promoter and Twist and the BMI-1 promoter in Hs578t cells.
Supplementary Figure 4 from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 84K, ERalpha knockdown in ERbeta overexpressing cells.
Supplementary Figure 3 from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 441K, LCC9 and MCF-7 ChIP assays.
Supplementary Figure 2 from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 154K, Effects of ER ligands on cell cycle in MCF-7 and LCC9 cells.
Supplementary Figure 1 from Preferential Estrogen Receptor β Ligands Reduce Bcl-2 Expression in Hormone-Resistant Breast Cancer Cells to Increase Autophagy
Authors: Ruddy Samantha C. , Lau Rosanna , Cabrita Miguel A. , McGregor Chelsea , McKay Bruce C. , Murphy Leigh C. , Wright James S. , Durst Tony , Pratt M.A. Christine
Published: April 2023

PDF - 130K, Effects of tamoxifen and fulvestrant on LCC9 and MCF-7 cell proliferation.
Supplementary Figures and Tables from Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Authors: Davis Sally J. , Sheppard Karen E. , Anglesio Michael S. , George Joshy , Traficante Nadia , Fereday Sian , Intermaggio Maria P. , Menon Usha , Gentry-Maharaj Aleksandra , Lubinski Jan , Gronwald Jacek , Pearce Celeste Leigh , Pike Malcolm C. , Wu Anna , Kommoss Stefan , Pfisterer Jacobus , du Bois Andreas , Hilpert Felix , Ramus Susan J. , Bowtell David D.L. , Huntsman David G. , Pearson Richard B. , Simpson Kaylene J. , Campbell Ian G. , Gorringe Kylie L.
Published: April 2023

Supplementary Figures S1 (Nanostring data and combined PFS for BMP8B and ATP13A4), S2 (Nanostring expression histograms), S3 (GAB2 survival by cohort), S4 (BMP8B and ATP13A4 survival by cohort), S5 (Metacore network maps); Supplementary Tables S2 (Cell line information), S3 (Univariate survival analysis results), S4 (Step-wise AIC results) and S6 (association of GAB2 expression with PRAS40).
Supplementary Table 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Authors: Yagishita Shigehiro , Fujita Yu , Kitazono Satoru , Ko Ryo , Nakadate Yusuke , Sawada Takeshi , Kitamura Yuka , Shimoyama Tatsu , Maeda Yoshiharu , Takahashi Fumiyuki , Takahashi Kazuhisa , Tamura Tomohide , Koizumi Fumiaki
Published: April 2023

Inhibitory concentration of 50% dose
Supplementary Figure Legend from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 73K
Supplementary Figure 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
Authors: Yagishita Shigehiro , Fujita Yu , Kitazono Satoru , Ko Ryo , Nakadate Yusuke , Sawada Takeshi , Kitamura Yuka , Shimoyama Tatsu , Maeda Yoshiharu , Takahashi Fumiyuki , Takahashi Kazuhisa , Tamura Tomohide , Koizumi Fumiaki
Published: April 2023

(A) WB analysis of HER2 expression after exposure of the indicated SCLC cells to CDDP at IC10 and IC50 concentrations for the indicated times. (B) WB analysis of HER2 expression after exposure of SBC-3 and SBC-5 cells to ETP and CPT-11 at their IC50 concentrations. All experiments were repeated at least three times with similar results. ETP: etoposide, CPT-11: irinotecan.
Supplementary Figure 6 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 51K, Structures of AG1478, Erlotinib, Gefitinib, PP1, PP2 and Dasatinib.
Supplementary Figure 5 from Src Mediates Cigarette Smoke–Induced Resistance to Tyrosine Kinase Inhibitors in NSCLC Cells
Authors: Filosto Simone , Baston David S. , Chung Samuel , Becker Cathleen R. , Goldkorn Tzipora
Published: April 2023

PDF file - 759K, Src binding to L858R MT EGFR is not sufficient to induce TKI resistance of the receptor (CS-dependent activation of Src may be involved). NIH-3T3 cells stably over-expressing the L858R MT EGFR were serum starved, incubated (or not) for 30 min. with 1 microM AG1478 and then exposed to EGF or CS, as before. A. Src and L858R MT EGFR bind each both with and without CS exposure. Src was IPed from total cell lysates and IBed for total EGFR and total Src. B. The L858R MT EGFR becomes resistant to TKI treatment during CS exposure. Tyr phosphorylation (p-YEGFR) and total EGFR protein levels were measured by IB in 50 microg of proteins from the cell lysates.
Supplementary Table 4 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

PDF - 138K, Adjuvant systemic treatments.
Supplementary Table 3 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

PDF - 36K, Samples tested.
Supplementary Table 1 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

XLSX - 13K, Table 1a. 182 genes across entire coding sequence Table 1b. 14 genes sequenced across selected introns.
Supplemental Table 2 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
Authors: Kinose Yasuto , Sawada Kenjiro , Makino Hiroshi , Ogura Tomonori , Mizuno Tomoko , Suzuki Noriko , Fujikawa Tomoyuki , Morii Eiichi , Nakamura Koji , Sawada Ikuko , Toda Aska , Hashimoto Kae , Isobe Aki , Mabuchi Seiji , Ohta Tsuyoshi , Itai Akiko , Morishige Ken-ichirou , Kurachi Hirohisa , Kimura Tadashi
Published: April 2023

Multivariate analysis for progression free survival of patients.
Supplemental Table 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
Authors: Kinose Yasuto , Sawada Kenjiro , Makino Hiroshi , Ogura Tomonori , Mizuno Tomoko , Suzuki Noriko , Fujikawa Tomoyuki , Morii Eiichi , Nakamura Koji , Sawada Ikuko , Toda Aska , Hashimoto Kae , Isobe Aki , Mabuchi Seiji , Ohta Tsuyoshi , Itai Akiko , Morishige Ken-ichirou , Kurachi Hirohisa , Kimura Tadashi
Published: April 2023

Characteristics of 94 ovarian cancer patients.
Suplpementary Table 2 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

XLSX - 22K, Substitution, insertion and deletion mutations/large structural alterations.
Supplemental Figure Legend from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
Authors: Kinose Yasuto , Sawada Kenjiro , Makino Hiroshi , Ogura Tomonori , Mizuno Tomoko , Suzuki Noriko , Fujikawa Tomoyuki , Morii Eiichi , Nakamura Koji , Sawada Ikuko , Toda Aska , Hashimoto Kae , Isobe Aki , Mabuchi Seiji , Ohta Tsuyoshi , Itai Akiko , Morishige Ken-ichirou , Kurachi Hirohisa , Kimura Tadashi
Published: April 2023

Supplemental Figure Legend.
Supplemental Figure 1 from IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment
Authors: Kinose Yasuto , Sawada Kenjiro , Makino Hiroshi , Ogura Tomonori , Mizuno Tomoko , Suzuki Noriko , Fujikawa Tomoyuki , Morii Eiichi , Nakamura Koji , Sawada Ikuko , Toda Aska , Hashimoto Kae , Isobe Aki , Mabuchi Seiji , Ohta Tsuyoshi , Itai Akiko , Morishige Ken-ichirou , Kurachi Hirohisa , Kimura Tadashi
Published: April 2023

Dose finding in vivo study of IMD-0354.
Supplementary Figure 2 from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Yang Joy , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

PDF file - 118K, Expression levels of anti-apoptotic proteins in LNCaP cells expressing p52 compared to control cells.
Supplementary Figure 1 from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Yang Joy , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

PDF file - 133K, Expression levels of members of the NF-kB family in LN-neo and LN-p52 cells.
Supplementary Figure Legends from SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
Authors: Brenca Monica , Rossi Sabrina , Lorenzetto Erica , Piccinin Elena , Piccinin Sara , Rossi Francesca Maria , Giuliano Alberto , Dei Tos Angelo Paolo , Maestro Roberta , Modena Piergiorgio
Published: April 2023

Supplementary Figure Legends � PDF file 51K, Supplementary Figure Legends
Supplementary Figure Legends from The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Authors: Musi Elgilda , Ambrosini Grazia , de Stanchina Elisa , Schwartz Gary K.
Published: April 2023

PDF file - 79KB
Supplementary Figure 3 from SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
Authors: Brenca Monica , Rossi Sabrina , Lorenzetto Erica , Piccinin Elena , Piccinin Sara , Rossi Francesca Maria , Giuliano Alberto , Dei Tos Angelo Paolo , Maestro Roberta , Modena Piergiorgio
Published: April 2023

Supplementary Figure 3 � PDF file 528K, Comparative analyses on G401 malignant rhabdoid tumor cell line
Supplementary Figure 3 from The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Authors: Musi Elgilda , Ambrosini Grazia , de Stanchina Elisa , Schwartz Gary K.
Published: April 2023

PDF file - 1199KB, AEB071/ BYL719 combination promotes apoptosis in GNAQ mutant xenograft model. At the end of treatments, two animals from each cohort were sacrificed and the tumors were assessed for apoptosis by TUNEL staining. See Methods for the details of this analysis.
Supplementary Figure 2 from SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
Authors: Brenca Monica , Rossi Sabrina , Lorenzetto Erica , Piccinin Elena , Piccinin Sara , Rossi Francesca Maria , Giuliano Alberto , Dei Tos Angelo Paolo , Maestro Roberta , Modena Piergiorgio
Published: April 2023

Supplementary Figure 2 � PDF file 371K, PCR-based mapping of SMARCB1 homozygous deletion in VAESBJ sarcoma cell line
Supplementary Figure 2 from The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Authors: Musi Elgilda , Ambrosini Grazia , de Stanchina Elisa , Schwartz Gary K.
Published: April 2023

PDF file - 405KB, AEB071/ BYL719 combination inhibits in vivo tumor growth in a GNA11 mutant xenograft model. A, Suppression of PKC/ ERK and PI3Kalpha/AKT pathways in Omm1 GNA11. Cells were treated with indicated AEB071/BYL719 concentrations for 2, 6 and 24 hrs and Western blots were then performed. alpha-Tubulin was used as a loading control. MARCKS and S6 inhibition was present but no AKT inhibition occurred with combination. ERK was inhibited by BYL719. B, AEB071/BYL719 inhibited tumor growth in a Omm1 xenograft model. AEB071/BYL719 inhibited tumor growth in a xenograft model with the GNA11 mutant Omm1 cell line. 6-8 week athymic female mice were subcutaneously injected with Omm1 cells. Drug treatments began after tumors reached 100 mm3. Mice with tumors were treated three times daily with AEB071 (80mg/kg/d) or once daily with BYL719 (50 mg/kg/d) or in combination for 5 days each week for a total of 3 weeks. Tumors were measured with calipers every 2 to 3 days. Tumor volume was compared between groups of mice at various points in time AEB071 or BYL719 alone. Toxicity was measured by weight loss.
Supplementary Figure 1 from The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Authors: Musi Elgilda , Ambrosini Grazia , de Stanchina Elisa , Schwartz Gary K.
Published: April 2023

PDF file - 399KB, AEB071/BYL719 synergistically inhibits GNAQ/GNA11 mutant tumor cell viability after 5 days of drug exposure. Chou-Toulay plots are shown with X-axis representing Fa, or fractional activity, and Y-axis representing combination index (CI) with <1, >1, and =1 indicating synergistic, antagonistic, and additive effects, respectively. Each point represents a different combination of drug concentrations used in the assay. Concentrations for AEB071 treatment include 0, 125, 250, 500, 1000 nM. Concentrations for BYL719 treatment include 0, 250, 500, 1000, 2000 nM. A table is also included showing Combination Indexes for each combination of AEB071 and BYL719 used in each cell line.
Supplementary Figure 3 from Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors
Authors: Fernandez-Fuente Gonzalo , Mollinedo Pilar , Grande Lara , Vazquez-Barquero Alfonso , Fernandez-Luna Jose L.
Published: April 2023

PDF - 1592K, PDGFR is not a modifier factor of GSC cell death in 3D substrates.
Supplementary Figure 2 from Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors
Authors: Fernandez-Fuente Gonzalo , Mollinedo Pilar , Grande Lara , Vazquez-Barquero Alfonso , Fernandez-Luna Jose L.
Published: April 2023

PDF - 1592K, Dimensionality does nor modify proliferation and differentiation of GSCs.
Supplementary Figure 1 from Culture Dimensionality Influences the Resistance of Glioblastoma Stem-like Cells to Multikinase Inhibitors
Authors: Fernandez-Fuente Gonzalo , Mollinedo Pilar , Grande Lara , Vazquez-Barquero Alfonso , Fernandez-Luna Jose L.
Published: April 2023

PDF - 667K, Apoptosis of GBM cell lines induced by sunitinib.
The inhibition of ANT2 suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Authors: Jang Ji-Young , Kim Yong-goo , Nam Soo Jeong , Keam Bhumsuk , Kim Tae Min , Jeon Yoon Kyung , Kim Chul Woo
Published: April 2023

Apoptosis analysis: cells were transfected with ANT2-specific shRNA or sc shRNA. At 24 h after transfection, the cells were treated with gefitinib (50 nM) or DMSO as a control and subsequently incubated for an additional 24 h. Then, cell were stained with annexin V-fluorescence isothiocyanate (FITC) and propidium iodide (PI) for flow cytometry analysis. Data are representative of three independent experiments.
Supplementary Table 2 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 72KB, Supplementary Table S2. Immunohistochemistry of mouse tumors treated for two weeks with vehicle control, niclosamide (20 mg/kg), TRA-8 (200 micro-g) or the combination of both agents. Tumors were stained and analyzed (H-score) for p-STAT3, cytosolic beta-catenin, nuclear beta-catenin and cleaved caspase 3. The values represent an average of three tumors per group (plus-minus SE).
Mitochondrial inhibitor, lonidamin suppresses cell viability and restores gefitinib sensitivity in EGFR-TKI-resistant NSCLC cells from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Authors: Jang Ji-Young , Kim Yong-goo , Nam Soo Jeong , Keam Bhumsuk , Kim Tae Min , Jeon Yoon Kyung , Kim Chul Woo
Published: April 2023

PC9, H1975, HCC827, and HCC827/GR cells were treated with lonidamine, gefitinib or DMSO as a control and subsequently incubated for an additional 24 h. Then, cell viability was measured using CCK8 assays and presented as a relative value compared to that of DMSO-treated cells. The values presented in all of the histograms are the mean values +/- SD.
Supplementary Table 1 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 89KB, Supplementary Table S1. Sensitivity of BLBC cell lines to niclosamide mediated cytotoxicity. SUM159, HCC1187, HCC1143 and 2LMP BLBC NAAE and adherent cell lines were treated with niclosamide for 48 hours and analyzed for viability using the ATPlite assay. Individual experiments were assayed in quadruplicate and values represent the mean and SD of three independent experiments. SUM159 P < 0.05, HCC1187 P < 0.05, HCC1143 P < 0.0005, 2LMP P > 0.05.
Down-regulation of ANT2 and HSP90 mRNA levels by siRNA from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Authors: Jang Ji-Young , Kim Yong-goo , Nam Soo Jeong , Keam Bhumsuk , Kim Tae Min , Jeon Yoon Kyung , Kim Chul Woo
Published: April 2023

H1975 cells were transfected with ANT siRNA, HSP90 siRNA or scramble (sc) siRNA. At 24 hours of transfection, expression levels of ANT2 and HSP90 were measured using qRT-PCR and the suppressive efficiency of siRNA was presented by relative expression levels (2-ddCt) of ANT2 and HSP90 compared with those of cells transfected with sc siRNA.
ANT2 inhibition sensitizes in A549 to gefitinib by down-regulating the levels of miR-221/222 from Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer
Authors: Jang Ji-Young , Kim Yong-goo , Nam Soo Jeong , Keam Bhumsuk , Kim Tae Min , Jeon Yoon Kyung , Kim Chul Woo
Published: April 2023

A549 cells were transfected with ANT2-specific shRNA or sc shRNA. At 24 hours of transfection, the expression levels of miR-221 and miR-222 were measured by qRT-PCR. The relative expression levels (2-ddCt) of these molecules were compared to those of cells transfected with sc shRNA.
Supplementary Figure 3 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 99KB, Supplementary Figure S3. ATPlite viability of cells treated with niclosamide. 2LMP, SUM159, HCC1143 and HCC1187 adherent (A) or NAAE (B) cells were treated with niclosamide for 24 hours and analyzed for viability using ATPlite assay. Individual experiments were assayed in triplicate and values represent the mean plus-minus SE.
Supplementary Methods, Figures 1 - 3 from Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo
Authors: Hussain Filza , Freissmuth Michael , Völkel Dirk , Thiele Michael , Douillard Patrice , Antoine Gerhard , Thurner Patrick , Ehrlich Hartmut , Schwarz Hans-Peter , Scheiflinger Friedrich , Kerschbaumer Randolf J.
Published: April 2023

PDF file - 247K, Suppl. Fig. 1. Pharmacokinetics of BaxG03 after intravenous and intraperitoneal injection; Suppl. Fig. 2. Trough plasma concentrations of BaxG03 after 28 days of administration; Suppl. Fig. 3. Dose-dependent inhibition of xenograft outgrowth by BaxB01 and BaxM159.
Supplementary Figure 1 from Effect of Niclosamide on Basal-like Breast Cancers
Authors: Londoño-Joshi Angelina I. , Arend Rebecca C. , Aristizabal Laura , Lu Wenyan , Samant Rajeev S. , Metge Brandon J. , Hidalgo Bertha , Grizzle William E. , Conner Michael , Forero-Torres Andres , LoBuglio Albert F. , Li Yonghe , Buchsbaum Donald J.
Published: April 2023

PDF file - 128KB, Supplementary Figure S1. Sensitivity of MF10A mammary epithelial cells to niclosamide and TRA-8 mediated cytotoxicity. (A) Attached MCF10A cell line was treated for 48 hours with niclosamide (0.08, 0.1, 0.25 and 0.5 microM) and analyzed for cell viability using ATPlite assay.
Supplementary Figures 1 through 6 and Supplementary Tables 1 through 3 from Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Authors: Fiskus Warren , Sharma Sunil , Qi Jun , Valenta John A. , Schaub Leasha J. , Shah Bhavin , Peth Karissa , Portier Bryce P. , Rodriguez Melissa , Devaraj Santhana G.T. , Zhan Ming , Sheng Jianting , Iyer Swaminathan P. , Bradner James E. , Bhalla Kapil N.
Published: April 2023

PDF - 352K, Supplemental Figure 1: Chemical structures of the molecules used in the studies. Supplemental Figure 2: Effects of (R)-JQ1 in AML cells. Supplemental Figure 3: ChIP of BRD4 and POLII in JQ1 treated AML cells. Supplemental Figure 4: JQ1 effects on CDK6 mRNA expression in AML cells. Supplemental Figure 5: JQ1 effects on mRNA and protein expression in FLT3-ITD expressing AML cells. Supplemental Figure 6: Isobologram analyses of BET protein antagonist and PS in AML cells. Supplemental Table 1: Clinical presentation and mutation status of primary AML samples. Supplemental Table 2: Top gene expression changes in AML cells following JQ1 treatment. Supplemental Table 3: Ingenuity Pathway analysis of AML cells following JQ1 treatment.
Supplementary Figure Legend from Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
Authors: Fiskus Warren , Sharma Sunil , Qi Jun , Valenta John A. , Schaub Leasha J. , Shah Bhavin , Peth Karissa , Portier Bryce P. , Rodriguez Melissa , Devaraj Santhana G.T. , Zhan Ming , Sheng Jianting , Iyer Swaminathan P. , Bradner James E. , Bhalla Kapil N.
Published: April 2023

PDF - 95K, Figure legends for the Supplemental Data.
Supplementary Figure 1 from Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Authors: Zhai Bo , Hu Fengli , Jiang Xian , Xu Jun , Zhao Dali , Liu Bing , Pan Shangha , Dong Xuesong , Tan Gang , Wei Zheng , Qiao Haiquan , Jiang Hongchi , Sun Xueying
Published: April 2023

PDF file - 109K, Supplementary Fig. S 1. Sorafenib-resistant cells responded poorly to sorafenib treatment in vivo.Parental Huh7 and Huh7-SR tumors were established in mice, which received different treatments for 15 days and then euthanize as described in Fig. 1, and Materials and Methods. The size (mm3) of tumors was recorded. "**" (P<0.001) indicate a highly significant difference from vehicle-treated Huh7 tumors; and "?" (P<0.001), a highly significant difference from sorafenib-treated Huh7 tumors.
Supplementary Figure 4 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Authors: Cerezo Michaël , Tichet Mélanie , Abbe Patricia , Ohanna Mickaël , Lehraiki Abdelali , Rouaud Florian , Allegra Maryline , Giacchero Damien , Bahadoran Philippe , Bertolotto Corine , Tartare-Deckert Sophie , Ballotti Robert , Rocchi Stéphane
Published: April 2023

PDF - 430K, (A) Upper panel, invasion assay in coated Boyden chambers with HMVII melanoma cells (mutated for p53) treated 24h after with metformin (at the indicated concentrations) or PBS for 24h.
Supplementary File from Overlapping Functions of ABC Transporters in Topotecan Disposition as Determined in Gene Knockout Mouse Models
Authors: Tiwari Amit K. , Zhang Rong , Gallo James M.
Published: April 2023

Supplementary File - PDF file 584K, Supplementary Figure 1: Total topotecan pharmacokinetic variables in Abc transporters knock out mouse models at two i.v. dose levels. ; Supplementary Figure 2: Urinary and fecal excretions of total topotecan in Abc transporters knock out mouse models at two i.v. dose levels. ; Supplementary Figure 3: Biliary flow and excretion rate of total topotecan in Abc transporters knock out mouse models at two i.v. dose levels. ; Supplementary Figure 4: Concentration-time plots for topotecan lactone and total (lactone+carboxylate forms) forms in Abc transporters knock out mouse models at two i.v. dose levels. ; Supplementary Table 1. Topotecan resistance as determined in ABC transporter over-expressing cells through MTT assay. ; Supplementary Table 2. Selected total topotecan pharmacokinetic parameters in Abc transporter knock out strains at two i.v. dose levels. ; Supplementary Table 3. Clinical chemistry parameters in the Abc transporters knock out strains
Supplementary Figure 2 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Authors: Cerezo Michaël , Tichet Mélanie , Abbe Patricia , Ohanna Mickaël , Lehraiki Abdelali , Rouaud Florian , Allegra Maryline , Giacchero Damien , Bahadoran Philippe , Bertolotto Corine , Tartare-Deckert Sophie , Ballotti Robert , Rocchi Stéphane
Published: April 2023

PDF - 248K, A375, 1205Lu or patient melanoma cells were treated 24h with metformin (at the indicated concentrations), 2h with staurosporine (1 microM) or PBS, lysed and analysed by Western-blot with PARP and caspase 3 antibodies.
Supplementary Figure 1 from Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
Authors: Cerezo Michaël , Tichet Mélanie , Abbe Patricia , Ohanna Mickaël , Lehraiki Abdelali , Rouaud Florian , Allegra Maryline , Giacchero Damien , Bahadoran Philippe , Bertolotto Corine , Tartare-Deckert Sophie , Ballotti Robert , Rocchi Stéphane
Published: April 2023

PDF - 34K, Effects of metformin on melanoma migration.
Supplementary Tables 1 - 5 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Authors: Zhong Lai-Ping , Zhu Dong-Wang , William William N. , Liu Ying , Ma Jie , Yang Cheng-Zhe , Yang Xiao , Wang Li-Zhen , Li Jiang , Myers Jeffrey N. , Lee J. Jack , Zhang Chen-Ping , Zhang Zhi-Yuan
Published: April 2023

PDF file - 81K, Supplemental table S1: Survival comparison between the cN2 patients treated with and without TPF induction chemotherapy. Supplemental table S2: Univariate Cox model analysis. Supplemental table S3: Multivariate Cox model analysis with interaction analysis. Supplemental table S4: Correlation between cyclin D1 expression and response to TPF induction chemotherapy. Supplemental table S5: Survival comparison between the cN2 patients treated with and without TPF induction chemotherapy according to cyclin D1 expression.
Supplementary Table 2 from ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells
Authors: Wang Shu , Chen Xiangyun Amy , Hu Jing , Jiang Jian-kang , Li Yunfei , Chan-Salis Ka Yim , Gu Ying , Chen Gong , Thomas Craig , Pugh B. Franklin , Wang Yanming
Published: April 2023

YW3-56 microarray data
Supplementary Figure 6 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Body weight plots for efficacy studies shown in figures 5 and 6.
Supplementary Data from Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
Authors: Tanaka Mamoru , Kataoka Hiromi , Yano Shigenobu , Ohi Hiromi , Moriwaki Kazuhiro , Akashi Haruo , Taguchi Takahiro , Hayashi Noriyuki , Hamano Shingo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Joh Takashi
Published: April 2023

PDF file - 74KB, 1H, 13C and 19F-NMR measurements.
Supplementary Figures 1 - 3 from Targeting Blockage of STAT3 in Hepatocellular Carcinoma Cells Augments NK Cell Functions via Reverse Hepatocellular Carcinoma–Induced Immune Suppression
Authors: Sun Xiaoxia , Sui Qiangjun , Zhang Cai , Tian Zhigang , Zhang Jian
Published: April 2023

PDF file - 745K, Figure S1 Blocking STAT3 in HCC reversed HCC-induced immune tolerance and promoted the antitumor effects of NK cells.; Figure S2 The expression of molecules associated with NK cell cytolytic activity was elevated by STAT3 blockade in HCC cells.; Figure S3 Subcellar localization of the STAT3 decoy ODN.
Supplementary Tables from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Table S1. List of 184 genes that interacts with MAP17 Supplementary Table S2. IC50 to bortezomib of cell lines expressing empty vector or MAP17